EFFICACY OF ARMODAFINIL IN PATIENTS WITH MODERATE TO SEVERE OSA AND RESIDUAL EXCESSIVE DAYTIME SLEEPINESS AFTER SUBOPTIMAL USAGE OF CPAP TREATMENT

Abstract

TYPE: Late Breaking Abstract TOPIC: Sleep Disorders PURPOSE: Large number of obstructive sleep apnea (OSA) patients treated with continuous positive airway pressure (CPAP) still experienced excessive daytime sleepiness (EDS), which affects quality of life and may discourage CPAP treatment. Armodafinil, wakefulness promoting agent, is approved for treating EDS in OSA patients who still experience EDS despite adequate CPAP usage. To date, there are no studies investigating effectiveness of early administration of Armodafinil with suboptimal CPAP usage. METHODS: A 12-week prospective cohort study was conducted on 30 OSA patients with suboptimal CPAP usage (2-<4 hours/night) who still experienced EDS. All patients received 150-mg Armodafinil daily and continued using CPAP. Efficacy and side effects were evaluated. RESULTS: 17/30 patients were analyzed for preliminary results after 4 weeks of Armodafinil therapy. Epworth Sleepiness Scale (ESS) was significantly decreased from 13±2.72points at baseline therapy to 6.40±3.50 points (p<0.001). Clinical Global Impression (CGI) rated by investigator and by patients were significantly decreased from 3.73±0.70 to 1.73±0.45 (p<0.001) and decreased from 3.35±0.63 to 1.78±0.57 (p<0.001); respectively. Pittsburg Sleep Quality Index (PSQI) was also significantly decreased from 9.67±3.99 to 6.13±3.06 (p<0.001). No serious side effects were observed. CONCLUSIONS: This is the first study conducted in moderate to severe OSA patients with residual EDS after suboptimal usage of CPAP treatment, in which administration of Armodafinil for 4-week- period was generally well tolerated with mild and self-limiting side effects. Armodafinil significantly reduced daytime sleepiness and improved sleep quality. Efficacy of Armodafinil at 12- week-period will be further analyzed. CLINICAL IMPLICATIONS: Early administration of Armodafinil can decrease EDS in subopimal CPAP usage patients. DISCLOSURE: No significant relationships. KEYWORD: Excessive daytime sleepiness